CANY
TVRD

Caxton Associates (New York)’s Tvardi Therapeutics TVRD Stock Holding History

Caxton Associates (New York)’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-610
Closed -$268K – 749
2021
Q4 		$268K Buy
+610
New +$307K 0.03% 445
2021
Q3 		– Sell
-491
Closed -$252K – 623
2021
Q2 		$252K Buy
+491
New +$311K 0.03% 361

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Caxton Associates (New York)'s TVRD Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Tvardi Therapeutics (TVRD) in Q1 2022, closing a stake of 610 shares — an estimated $268K sold.

Caxton Associates (New York) first reported a position in TVRD in Q2 2021 and held it in 2 quarters. The position peaked at $268K in Q4 2021. 183 funds tracked by Wall St. Rank hold TVRD as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Tvardi Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 610 Tvardi Therapeutics shares in Q1 2022, an estimated $268K.
  • Caxton Associates (New York) first reported a position in Tvardi Therapeutics in Q2 2021 and held it in 2 quarters.
  • Caxton Associates (New York)'s Tvardi Therapeutics position peaked at $268K in Q4 2021.
  • 183 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.